# A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

> **NCT04414475** · PHASE2 · RECRUITING · sponsor: **Karyopharm Therapeutics Inc** · enrollment: 127 (estimated)

## Conditions studied

- Multiple Myeloma, Refractory

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Dexamethasone
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT04414475
- **Lead sponsor:** Karyopharm Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-01
- **Primary completion:** 2028-01
- **Final completion:** 2028-01
- **Target enrollment:** 127 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04414475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04414475, "A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04414475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*